2017
DOI: 10.1016/j.ophtha.2017.03.052
|View full text |Cite|
|
Sign up to set email alerts
|

United States Multicenter Clinical Trial of Corneal Collagen Crosslinking for Keratoconus Treatment

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

9
150
3
6

Year Published

2017
2017
2021
2021

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 188 publications
(168 citation statements)
references
References 43 publications
9
150
3
6
Order By: Relevance
“…Hersh et al. () reported 3 of 102 eyes having clinically significant corneal haze at 1 year after C‐CXL. Bozkurt et al.…”
Section: Discussionmentioning
confidence: 99%
“…Hersh et al. () reported 3 of 102 eyes having clinically significant corneal haze at 1 year after C‐CXL. Bozkurt et al.…”
Section: Discussionmentioning
confidence: 99%
“…Several studies have reported improvements in visual acuity following CXL (Ivarsen & Hjortdal, 2013; Hersh et al, 2017). Direct illumination of UVA-light towards the eye has raised concerns with regards to the safety of CXL.…”
Section: Keratoconusmentioning
confidence: 99%
“…98 Also, since the role of inflammation in the development of symptoms is welldefined, many studies have suggested anti-inflammatory agents administration. For instance, corneal collagen crosslinking is reported to be effective in improving the maximum keratometry value and slowing down the progression of the disease, with an excellent safety profile.…”
Section: Discussionmentioning
confidence: 99%